The Cognito Platform is a medical device that offers non-invasive neuromodulation to potentially improve outcomes in neurodegenerative diseases, such as Alzheimer’s. Developed by MIT and clinically validated over several years, the device is personalized based on the individual’s brain responses.

One of the standout features of the Cognito Platform is its ability to offer personalized treatments that are adjustable to fit the patient’s needs. This device can be self-administered in the comfort of the patient’s home, making it a convenient option for those with busy schedules or mobility issues.

Cognito’s personalized sensory stimulation is designed to facilitate long-term engagement, ensuring that patients remain active in their treatment and can benefit from its effects over time. The device is also user-friendly, with support readily available at the touch of a button.

By evoking gamma oscillations in the brain, the Cognito Platform enhances synaptic connections between neurons, activates microglia, and promotes the removal of pathological proteins from the brain. This results in reduced neurodegeneration and brain atrophy, as well as improved sleep, cognitive, and functional abilities.

The Cognito Platform is a promising option for individuals looking to manage their neurodegenerative conditions in a convenient and personalized way.

Twitter Page of the Solution

linkedin Page of the Solution

Website of the Solution